latest news releases from the newsroom
W2 Energy Inc.
W2 Energy Inc. Signs Financial Engagement Letter With ABB
NEW YORK, Nov. 7, 2005 (PRIMEZONE) -- W2 Energy Inc. (Pink Sheets:WWEN), a developer of Green Energy, is pleased to announce it has signed a financial engagement letter with ABB of Norwalk, CT. Under the terms of the letter, ABB will assist in sourcing funds, either debt or equity, via its world-wide project and trade finance network for W2 Energy Inc.'s 10,000 barrel per/day 100MW combination biomass to GTL/electricity plant to be located in Guelph, Ontario. The terms of the agreement state upon successful financing, ABB will be paid a success fee of one (1) percent of the total project financing. ABB will also assist in the complete turnkey installation and engineering of all electrical generators and electrical systems.
Scanditronix-Wellhofer and RaySearch Sign Letter of Intent Regarding Quality Assurance of IMRT
STOCKHOLM, Sweden, Nov. 7, 2005 (PRIMEZONE) -- RaySearch Laboratories AB announce that a letter of intent has been signed with Scanditronix-Wellhofer to enter into a long-term development and license agreement regarding new products for quality assurance of IMRT. RaySearch is a world leader in treatment planning for IMRT and in advanced software applications for radiation therapy of cancer. Scanditronix-Wellhofer is a world leader in advanced dosimetry and quality assurance solutions for clinical and industrial radiation applications.
Hydro Participates in Alunorte Alumina Expansion
OSLO, Norway, Nov. 7, 2005 (PRIMEZONE) -- Hydro will participate in the investment to increase alumina capacity at the highly competitive Alunorte refinery in Brazil. The expansion will raise annual capacity by more than 40 percent to approximately 6.5 million tonnes, making the refinery the largest and most modern in the world.
TeliaSonera Closes Deal and Acquires Chess/Sense
STOCKHOLM, Sweden, Nov. 7, 2005 (PRIMEZONE) -- TeliaSonera today announced that it had closed the deal with Vollvik Gruppen AS, 100 percent owner of Chess/Sense in Norway, to acquire 91.2 percent of the shares. The agreed price is NOK 11.03 in cash per Vollvik Gruppen AS share, equalling a total acquisition price of SEK 1,895 million (NOK 1,619 million).
Kos and Jerini Sign Exclusive Collaboration and License Agreement for Development, Marketing and Distribution of Icatibant in The United States and Canada
CRANBURY, N.J. and BERLIN, Nov. 7, 2005 (PRIMEZONE) -- Kos Life Sciences, Inc., a subsidiary of Kos Pharmaceuticals, Inc. (Nasdaq:KOSP) and Jerini U.S. Inc., a subsidiary of Jerini AG (FSE:JI4), announced today the signing of an exclusive agreement for the development, marketing and distribution of Jerini's compound, Icatibant, a potent and specific peptidomimetic bradykinin B2 receptor antagonist, in the United States and Canada. The strategic partnership includes an upfront licensing payment of EUR 12 million (approx. $15 million), along with a EUR 10 million (approx. $12 million) equity investment out of a capital increase at the higher of the weighted average of the closing price of Jerini's shares during the last four trading days, or EUR 3.20 (approx. $3.84) per share (IPO price). Undisclosed milestone payments and sales royalties are also specified in the agreement. Hereditary angioedema (HAE) is the first of several diseases for which Icatibant offers a potential treatment. The agreement outlines collaboration in the HAE area as well as other forms of angioedema, asthma, and refractory ascites in liver cirrhosis (RAIL) indications. Proof-of-concept trials have already been completed in these indications.
MorphoSys and Wacker Demonstrate High Yield Expression of Antibody Fragments
MARTINSRIED, Germany, Nov. 7, 2005 (PRIMEZONE) -- A feasibility study conducted by Wacker Biotech GmbH on behalf of MorphoSys AG (Frankfurt:MOR) (Prime Standard Segment, TecDAX) using Fab fragments, demonstrated that Wacker's E. coli secretion system can offer a far simpler and more cost-effective way of obtaining high yields of antibody fragments, which are used for research, diagnostic and therapeutic applications. Under the joint agreement, MorphoSys obtains the right to use Wacker's secretion system for antibody-fragment production in research quantities for therapeutic projects both on its own behalf and with its commercial partners.